A
Guide to Cardiovascular Issues in CFS IVc: Peroxynitrite and the Heart
by Cort Johnson
The Sieverling paper reports Dr. Cheney believes
peroxynitrite is the central agent of damage of heart failure both in the
idiopathic cardiomyopathy Dr. Cheney experienced and in CFS patients. Most of
the treatments Dr. Cheney recommends are aimed at reducing nitric oxide,
superoxide or peroxynitrite levels.
For such a well researched subject it is
surprising that peroxynitrite was only discovered about 15 years ago.
Peroxynitrite is formed and vanishes so quickly it is almost impossible to
measure in the body. Really potent free radicals are so imbalanced that they
often quickly revert to a more balanced state. Instead of measuring
peroxynitrite directly, researchers usually determine its presence by measuring
one of its by-products, 3-nitrotyrosine, which is formed when peroxynitrite
nitrates the tyrosine amino acids in proteins. Thus while it is possible to
determine the positive or negative aspects of peroxynitrite, it is difficult to
tell exactly how it achieves them.
The Bad
- In vitro tests of
peroxynitrite’s effect on the animal hearts indicate it increases lipid
peroxidation (cell membrane damage), depletes antioxidant levels (leaving cells
vulnerable to free radicals), disrupts intracellular signaling (throws a monkey
wrench into the machinery), dysregulates intracellular calcium levels (causing
cell suicide among other things), inhibits contractile protein activity (reduces
heart pumping), injures DNA and increases cell adhesion to the vascular wall
(increasing inflammation, atherosclerosis) (Pacher et al. 2005, Hare and Stamler
2005) (!!!!). By oxidizing BH4 peroxynitrite may also play a role in both
reduced NO production and increased superoxide production.
Both nitric oxide and peroxynitrite can inhibit
mitochondrial electron transport (ATP production) through inactivation of
complexes I, II, III in the electron transport chain. Protein nitration (nitrotyrosine
formation) also knocks out or alters the activity of the main superoxide
scavenger in the mitochondria MnSOD. The position of the tyrosine residues near
cytochrome C’s catalytic region renders it particularly susceptible to
peroxynitrite damage (Cassina et. al. 2000, Reiter et. al. 2000). Peroxynitrite
does its damage by oxidizing the lipids (fats) in cell membranes (they are very
fatty), by fragmenting DNA and by damaging (nitrating) proteins.
During pathologic conditions such as
hypertension (high blood pressure), high cholesterol, and during the early
moments of the reperfusion process, both NO and superoxide and therefore
peroxynitrite are produced in large amounts (Ronson et. al. 1999 ). Besides its
direct negative effects peroxynitrite can potentially have indirect negative
effects simply because so much NO is used up making it. This results in low
levels of NO, which we have seen is an important anti-oxidant, vasodilator and
mitochondrial regulator.
Peroxynitrite appears to be particularly
involved in two aspects of cardiovascular health; ischemia-reperfusion and
coronary artery disease.
Peroxynitrite and
ischemia-reperfusion –
As noted earlier ischemia occurs when low blood flows cause tissue damage. After
ischemic tissues are reperfused with blood high levels of free radicals,
including peroxynitrite, superoxide and the hydroxyl radical are formed. As
neutrophils and macrophages ‘clean up’ cells that have been killed by low blood
flows they release large amounts of reactive oxygen species that can cause
further tissue damage. Interestingly, macrophages in reperfused tissues often
have become reduced in L-arg, a condition which causes them to produce both
superoxide and nitric oxide and thus peroxynitrite (Ronson et. al. 1999)
Ischemic injury to the heart muscle most often
occurs through blockage of the coronary arteries but it can also occur through
blockage of the smaller blood vessels that feed the heart itself. Since CFS
patients do not appear overly susceptible to heart attack (or small vessel
blockage?) it us unclear how much they have to worry about peroxynitrite formed
through ischemia-reperfusion (?).
Ischemic episodes can, however, chronically
occur when increased demand occurs in the context of chronically low cardiac
blood flows (Dewald et. al. 2003). The diversion of blood to one tissue
during conditions of low blood flows apparently results in the pathologically
low blood flows to other tissues. One wonders if this occurs systemically in
people with low blood volume; a subset of CFS patients have low blood volume.
Ischemic episodes in mice result in chemokine production, ROS formation and
inflammation. This results in macrophage infiltration, fibrosis (fiber
deposition in the heart) and contributes to diastolic restriction (i.e. left
ventricular stiffening).
Peroxynitrite and
atherosclerosis
- The discovery almost 25
years ago that oxidatively damaged LDL cholesterol particles were attacked by
macrophages gave rise to several decades of intense research to determine the
effects this had on the process of atherosclerosis. Peroxynitrite production in
atherosclerotic lesions is strikingly high and exceeds that found in
non-pathologic LDL particles by 90x’s (!) While much research has indicated that
oxidation of the lipid membranes surrounding LDL cholesterol particles plays a
key role in atherosclerosis, it is still unclear whether it is the cause of the
disease (Rubbo and O’Donnell 2005).
Peroxynitrite appears to be the main agent of
LDL cholesterol oxidation. Exactly how peroxynitrite oxidizes LDL particle,
however, is still not clear. A macrophage attack on these particles produces a
cholesteryl ester which promotes the formation of the ‘fatty streaks’ on the
artery wall that eventuate in the production of plaque. Since peroxynitrite very
rapidly ‘protonates’ to form peroxynitrous acid (ONOOH) or via H+ or CO2 a
number of other compounds (nitrogen dioxide (NO2), hydroxyl radical (OH-) or the
carbonate anion radical (CO3-), each of which can have negative effects, it is
difficult to know if its peroxynitrite or one of its by-products that does the
actual damage in atherosclerosis.
CFS patients are not dropping dead from heart
attack nor do they appear susceptible to coronary artery disease.
And Good (yes, the GOOD) of
Peroxynitrite
– Several in vitro
studies have indicated increased peroxynitrite levels in perfused rodent hearts
negatively effect heart contraction; an outcome believed due to peroxynitrites
ability to inhibit oxidative metabolism (energy production). Reperfusion
occurs when hearts that have been deprived with blood are then re-perfused with
it. In vitro tests usually use a buffering solution rather than actual blood. As
we shall see below this may skew the test results.
In vivo
studies (i.e. in the living body) however, have found that the same
levels of peroxynitrite infusion that damaged hearts in vitro tests had
protective effects on heart tissues. Accumulations of neutrophils (myeloperoxidase
activity) were less in hearts perfused with peroxynitrite than in those without
it and systolic functioning was improved (Ronson et. al. 1999). Peroxynitrite
infusions at higher levels, however, (10-20x’s higher) had negative effects. A
follow up study employing intermediate peroxynitrite levels found it to be
cardioprotective at those levels. Bizarrely, extremely high levels of
peroxynitrite infusion stopped endothelial dysfunction (increased vasodilation)
and thus were protective. This paradoxical finding was believed due to
sensitization of the endothelium to the ischemic-reperfusion process (?).
Nitrosothiols
- Depending on its concentration,
then, peroxynitrite can either have positive or negative effects on the vascular
endothelium, coronary arteries and/or the heart muscle. How could this
incredibly reactive free radical be beneficial to the heart? It turns out that
when glutathione or other thiol agents (albumin, cysteine) interact with
peroxynitrite they produce an agent called a nitrosothiol which has
anti-inflammatory and pro-vasodilatory effects. The cardioprotective effects of
nitrosothiols could derive from three processes; they have the ability to (a)
terminate the free radical chain reaction process, (b) lower intracellular
calcium concentrations by stimulating cGMP production, (c) inhibit leukocyte
adhesion through NO release. Glutathione has been shown to increase heart
vasodilation; it is now thought its vasodilatory properties are due to its
interactions with low levels of ONOO- present during basal (non-pathogenic)
conditions (Cheung et. al. 2000). This, of course, suggests a) reduced
glutathione levels could impair vascular functioning and b) glutathione
supplementation may be helpful in heart failure.
It is possible the negative/positive effects of
peroxynitrite depend on the peroxynitrite/thiol balance. As soon as the levels
of peroxynitrite exceed the ability of thiols to transform it its negative
effects may begin to occur. High rates of peroxynitrite induction during
atherosclerosis, ischemia-reperfusion, etc. apparently exceed the bodies ability
to transform it into a useful substance.
(A recent paper, however, that suggests
nitrosothiols are not as beneficial as they may seem once again illustrates how
complex oxidant:antioxidant interactions are (Kitagawa et. al. 2005.While
nitrosothiols have beneficial properties they may degrade into substances that
are anything but benign. The degree to which this occurs in the body is,
however, unclear.)
Summary
- Peroxynitrite production plays a
significant role in the progression of one of the great killers of our time,
atherosclerosis. It also appears to depress heart contractility, impair
endothelial functioning and vasodilation, deplete antioxidant levels and
contribute to the damage caused by the ischemia/reperfusion process. In
non-pathological situations, however, peroxynitrite interacts with glutathione
and other thiols to produce substances (nitrosothiols) that appear to have
decidedly positive effects on the heart. Whether peroxynitrite has negative or
positive effects is at least in part, therefore, dependent upon the whether
sufficient thiol agents, in particular glutathione, are present to transform it
into not just a benign but a helpful agent.
_________________________________
Cassina, A., Hodara, R., Sousa, J., Thomson, L.,
Castro, L., Ischiropoulos, H., Freeman, B. and R. Radi. 2000. Cytochrome c
nitration by peroxynitrite. The Journal of Biological Chemistry 275:
21409-21415.
Cheung, P., Wang, W. and R. Schulz. 2000.
Glutathione protects against myocardial ischemia-reperfusion injury by
detoxifying peroxynitrite. J. Mol. Cell. Cardio. 32: 1669-1678.
Dewald
Hare, J. and J. Stamler. 2005. No/redox
disequilibrium in the failing heart and cardiovascular system. The Journal of
Clinical Investigation 115: 509-517.
Kitigawa
Pacher, P., Schulz, R., Liaudet, L. and C. Szabo.
2005. Nitrosative stress and pharmacological modulation of heart failure. Trends
in Pharmacological Sciences 26, 302-310.
Reiter, C., Teng, R. and J. Beckman. 2000.
Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via
peroxynitrite. The Journal of Biological Chemistry 275: 32460-32466.
Ronson, R., Nakamura, M. and J. Vinten-Johansen.
1999. The cardiovascular effects and implications of peroxynitrite.
Cardiovascular Research 44, 47-59.
Rubbo, H and V. O’Donnell. 2005. Nitric oxide,
peroxynitrite and lipoxygenase in atherogenesis: mechanistic insights.
Siwik, D., Tzortzis, J., Pimental, D., Chang,
D., Pagano, P., Singh, K., Sawyer, D. and W. Colucci. 1999. Circ. Res. 85:
147-153.